Clinical trials
Completed Cardiac Output, Low trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 3 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 59 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Innogene Kalbiotech Pte. Ltd | 2 |
| Karolinska Institutet | 2 |
| Klinikum Ludwigshafen | 2 |
| Medical University of Warsaw | 2 |
| University of Iowa | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Arcothova | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Azienda Sanitaria-Universitaria Integrata di Udine | 1 |
| Bambino Gesù Hospital and Research Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiac Output, Low | 59 |
| Cardiac Output, High | 9 |
| Heart Defects, Congenital | 6 |
| Heart Failure | 4 |
| Hypovolemia | 3 |
| Aneurysm | 2 |
| Renal Insufficiency | 2 |
| Shock, Cardiogenic | 2 |
| Transposition of Great Vessels | 2 |
| Acute Coronary Syndrome | 1 |
Trials
Showing 1 to 25 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.